Oliver Barnes

Joining the discussion are Oliver Barnes, an FT U.S. deals correspondent, and Claire Jones, FT U.S. economics editor. They dive into Pfizer's fierce legal battle against Novo Nordisk over the MetSera bidding war, exploring its potential implications on weight-loss drug innovation. Claire sheds light on U.S. policy discussions regarding global dollar adoption, detailing candidate countries and the challenges they face. Both guests provide keen insights into the intersection of healthcare and economic policy in today's market.

In this engaging discussion, Oliver Barnes, U.S. deals and activism correspondent for the Financial Times, delves into the fierce $10 billion battle between Pfizer and Novo Nordisk over the biotech startup MetSera. He outlines why weight-loss drugs have become crucial for both companies and explains the unique bidding strategies employed. Topics include Novo's unsolicited bid, Pfizer's accusations of bribery, and the political drama surrounding the FTC's involvement. With high stakes in play, the showdown reveals the urgent demand for innovative obesity treatments.

Oliver Barnes, FT deals and activism correspondent, breaks down the bidding chaos around Warner Bros. Chris Grimes, FT Los Angeles bureau chief, explains Hollywood power plays and industry fallout. They cover Netflix and Paramount’s clash, Trump’s ties to bidders, DOJ antitrust scrutiny, activist investor moves and the high-stakes shareholder vote to watch next.